417 related articles for article (PubMed ID: 12146575)
1. Assessment of four biochemical markers of bone metabolism in postmenopausal osteoporosis.
Majkić-Singh N; Ilić M; Ignjatović S; Aleksandra-Postić-Grujin
Clin Lab; 2002; 48(7-8):407-13. PubMed ID: 12146575
[TBL] [Abstract][Full Text] [Related]
2. Body mass index (BMI) and parameters of bone formation and resorption in postmenopausal women.
Papakitsou EF; Margioris AN; Dretakis KE; Trovas G; Zoras U; Lyritis G; Dretakis EK; Stergiopoulos K
Maturitas; 2004 Mar; 47(3):185-93. PubMed ID: 15036488
[TBL] [Abstract][Full Text] [Related]
3. Effects of chronic liver disease on bone mineral density and bone metabolism markers in postmenopausal women.
Uretmen S; Gol M; Cimrin D; Irmak E
Eur J Obstet Gynecol Reprod Biol; 2005 Nov; 123(1):67-71. PubMed ID: 16051419
[TBL] [Abstract][Full Text] [Related]
4. Normal osteoclastic and osteoblastic responses to exogenous growth hormone in patients with postmenopausal spinal osteoporosis.
Kassem M; Brixen K; Blum WF; Mosekilde L; Eriksen EF
J Bone Miner Res; 1994 Sep; 9(9):1365-70. PubMed ID: 7817819
[TBL] [Abstract][Full Text] [Related]
5. Correlations of serum prolidase activity between bone turnover markers and mineral density in postmenopausal osteoporosis.
Verit FF; Geyikli I; Yazgan P; Celik A
Arch Gynecol Obstet; 2006 Jun; 274(3):133-7. PubMed ID: 16532321
[TBL] [Abstract][Full Text] [Related]
6. [Biochemical markers of bone turnover : clinical usefulness in osteoporosis].
Garnero P; Delmas PD
Ann Biol Clin (Paris); 1999; 57(2):137-48. PubMed ID: 10210740
[TBL] [Abstract][Full Text] [Related]
7. Effects of low-dose prednisone on bone metabolism.
Ton FN; Gunawardene SC; Lee H; Neer RM
J Bone Miner Res; 2005 Mar; 20(3):464-70. PubMed ID: 15746991
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the relationship between dynamic pattern of nighttime levels of melatonin and chosen biochemical markers of bone metabolism in a rat model of postmenopausal osteoporosis.
Ostrowska Z; Kos-Kudla B; Swietochowska E; Marek B; Kajdaniuk D; Górski J
Neuro Endocrinol Lett; 2001 Apr; 22(2):129-36. PubMed ID: 11335889
[TBL] [Abstract][Full Text] [Related]
9. Bone markers: biochemical and clinical significance.
Lello S; Paoletti AM; Migliaccio S; Melis GB
Aging Clin Exp Res; 2004 Jun; 16 Suppl(3):33-6. PubMed ID: 15506699
[No Abstract] [Full Text] [Related]
10. Biochemical markers of bone turnover: an update.
van Daele PL; Birkenhäger JC; Pols HA
Neth J Med; 1994 Feb; 44(2):65-72. PubMed ID: 8208326
[TBL] [Abstract][Full Text] [Related]
11. Comparison of markers for bone formation and resorption in premenopausal and postmenopausal subjects, and osteoporosis patients.
Kushida K; Takahashi M; Kawana K; Inoue T
J Clin Endocrinol Metab; 1995 Aug; 80(8):2447-50. PubMed ID: 7629240
[TBL] [Abstract][Full Text] [Related]
12. Changes of bone formation markers osteocalcin and bone-specific alkaline phosphatase in postmenopausal women with osteoporosis.
Lumachi F; Ermani M; Camozzi V; Tombolan V; Luisetto G
Ann N Y Acad Sci; 2009 Sep; 1173 Suppl 1():E60-3. PubMed ID: 19751416
[TBL] [Abstract][Full Text] [Related]
13. Evidence for increased bone formation following a brief endurance-type training intervention in adolescent males.
Eliakim A; Raisz LG; Brasel JA; Cooper DM
J Bone Miner Res; 1997 Oct; 12(10):1708-13. PubMed ID: 9333132
[TBL] [Abstract][Full Text] [Related]
14. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
[TBL] [Abstract][Full Text] [Related]
15. Serum insulin/like growth factor I, bone mineral density and biochemical markers of bone metabolism in children with idiopathic osteoporosis.
Chlebna-Sokol D; Rusinska A
Endocr Regul; 2001 Dec; 35(4):201-8. PubMed ID: 11858767
[TBL] [Abstract][Full Text] [Related]
16. Clinical usefulness of measurements of urinary deoxypyridinoline (DPD) in patients with postmenopausal osteoporosis receiving intermittent cyclical etidronate: advantage of free form of DPD over total DPD in predicting treatment efficacy.
Kitatani K; Nakatsuka K; Naka H; Miki T; Morii H; Nishizawa Y
J Bone Miner Metab; 2003; 21(4):217-24. PubMed ID: 12811626
[TBL] [Abstract][Full Text] [Related]
17. Influence of sex and age on biochemical bone metabolism parameters.
Resch H; Pietschmann P; Kudlacek S; Woloszczuk W; Krexner E; Bernecker P; Willvonseder R
Miner Electrolyte Metab; 1994; 20(3):117-21. PubMed ID: 7815999
[TBL] [Abstract][Full Text] [Related]
18. Levels of biochemical bone marker procollagen type I N-propeptide (PINP) in Thai women aged 40-70 years.
Boonyanurak P; Wilawan K
J Med Assoc Thai; 2009 Jul; 92(7):873-7. PubMed ID: 19626803
[TBL] [Abstract][Full Text] [Related]
19. Changes in biochemical parameters of bone turnover and bone mineral density in post-pregnancy osteoporosis.
Honjo S; Mizunuma H
Am J Obstet Gynecol; 2001 Jul; 185(1):246-7. PubMed ID: 11483939
[TBL] [Abstract][Full Text] [Related]
20. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]